Novartis’ (NOVN: VX) results show the firm humming along nicely in 2024, with sales driven by continued strong performance ...

Novartis AG released its Annual Report for 2024, alongside its ‘Novartis in Society – Integrated Report 2024.’ This announcement underscores the company ...

Novartis AG (NYSE:NVS), a global healthcare company valued at over $206 billion, has undergone significant transformation in recent years, focusing its efforts on becoming a pure-play pharmaceutical ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

In a report released today, Eric Le Berrigaud from Stifel Nicolaus maintained a Hold rating on Novartis AG (NOVN – Research Report), with a ...

Bank of America Securities analyst Graham Parry has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with ...

Looking ahead to 2025, Novartis maintains an optimistic stance, forecasting mid to high single-digit sales growth and anticipating even stronger operational core earnings in the high single to low ...

The "Cholesterol Testing Products and Services Market by Product, by Test Cholesterol Tests, by Application, by End-User, and ...

Analysts at Zacks Research boosted their FY2025 EPS estimates for Novartis in a research note issued to investors on ...

Greece on Monday prosecuted a pair of protected witnesses in a long-running bribery probe involving Swiss pharmaceutical firm Novartis for alleged perjury, a justice source said.

Novartis sues HHS over rejection of a proposed 340B rebate model, arguing it enhances transparency and compliance while ...

Ameritas Advisory Services LLC lowered its position in shares of Novartis AG (NYSE:NVS – Free Report) by 2.7% during the 4th ...